Skip to main content
. 2017 Mar 6;8(20):32550–32565. doi: 10.18632/oncotarget.15925

Figure 6. ASC treatment causes inhibition of activated FLT3 signaling.

Figure 6

The FLT3-ITD mutated MV4;11 cell line was treated for 24 hours with increasing ASC doses, ranging from 0.2 μmol/L up to 5 μmol/L, and then analyzed by Western blot analysis, using FLT3, p-FLT3, STAT5 and p-STAT5 antibodies.